Cannabinoid, CB1 agonists in cervical dystonia: Failure in a phase IIa randomized controlled trial

Cindy Zadikoff, P. M. Wadia, J. Miyasaki, R. Chen, A. E. Lang, J. So, S. H. Fox*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

Background: Dystonia may result from reduced GABAergic transmission in the external globus pallidus (GPe). Cannabinoid CB1 agonists enhance GABA in the GPe and may therefore reduce dystonia. Objectives: To determine the efficacy of the cannabinoid CB1 agonist, dronabinol, in cervical dystonia (CD). Methods: Nine patients with CD were randomised to dronabinol (15. mg/d)/placebo in an 8-week crossover trial. Outcome measures included TWSTRS, visual analog scale of pain, global impression of change and adverse events (AEs). Results: There was no effect of dronabinol compared to placebo on any outcome measure (all P> 0.05, n= 7). One subject withdrew due to AEs and one was lost to follow-up. Mild AEs were experienced by all. Conclusions: Short-term use of dronabinol in CD has no benefit. Despite the study limitations, cannabinoids are unlikely to be useful in the treatment of dystonia.

Original languageEnglish (US)
Pages (from-to)91-95
Number of pages5
JournalBasal Ganglia
Volume1
Issue number2
DOIs
StatePublished - Jul 1 2011

Keywords

  • Cannabinoids
  • Cervical dystonia
  • Dronabinol
  • Randomised controlled trial

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Cannabinoid, CB1 agonists in cervical dystonia: Failure in a phase IIa randomized controlled trial'. Together they form a unique fingerprint.

Cite this